{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:12:40Z","timestamp":1791695560019,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"bill and melinda gates foundation","doi-asserted-by":"publisher","award":["OPP1032115"],"award-info":[{"award-number":["OPP1032115"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"united states agency for international development","doi-asserted-by":"publisher","award":["AID-OAA-A-15\u201300045"],"award-info":[{"award-number":["AID-OAA-A-15\u201300045"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"swedish international development cooperation agency","doi-asserted-by":"crossref","award":["2017\/762965\u20130"],"award-info":[{"award-number":["2017\/762965\u20130"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001322","name":"south african medical research council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006661","name":"united nations population fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"match research unit"},{"name":"government of south africa"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV incidence among women in Eastern and Southern Africa remains unacceptably high, highlighting the need for effective HIV prevention options, including pre-exposure prophylaxis (PrEP). The Evidence for Contraceptive Options and HIV Outcomes trial offered daily oral PrEP to participants during the latter part of the clinical trial as an additional HIV prevention choice. We explored daily oral PrEP continuation at trial exit among women enrolled from Durban, South Africa who initiated oral PrEP at the trial site. Of the 132 women initiating oral PrEP, 87% reported continuation of oral PrEP at month 1, 80% at month 3, and 75% continued using oral PrEP at their final trial visit and were referred to off-site facilities for ongoing oral PrEP access. The median duration of oral PrEP use in trial participants who used oral PrEP was 91\u00a0days (IQR 87 to 142\u00a0days). Women who disclosed their oral PrEP use to someone had increased odds of continuing oral PrEP at trial exit. Women who reported\u2009&gt;\u20091 sex partner and those who felt they would probably or definitely get infected with HIV had reduced odds of continuing oral PrEP at trial exit. Of those discontinuing oral PrEP (n\u2009=\u200932),\u2009&gt;\u200950% discontinued within the first month, and the most common reason for discontinuation was reporting side effects. The high rates of oral PrEP continuation in our study are encouraging and our findings can be utilized by other clinical trials providing oral PrEP as standard of care for HIV prevention and by oral PrEP implementation programmes.<\/jats:p>","DOI":"10.1007\/s10461-022-03592-x","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T09:02:27Z","timestamp":1644051747000},"page":"2623-2631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-8123","authenticated-orcid":false,"given":"Ivana","family":"Beesham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvora L.","family":"Joseph Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mags","family":"Beksinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"3592_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global AIDS Update 2020 Report: Seizing the Moment\u2014Tackling entrenched inequalities to end epidemics. UNAIDS. 2020. Geneva, Switzerland."},{"key":"3592_CR2","unstructured":"Joint United Nations Programme on HIV\/AIDS. (2020). Country Fact Sheets: South Africa (2019). https:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica. Accessed 15 March 2021."},{"issue":"Suppl 3","key":"3592_CR3","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1086\/651483","volume":"50","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010;50(Suppl 3):S122\u20139.","journal-title":"Clin Infect Dis"},{"key":"3592_CR4","unstructured":"Centers for Disease Control and Prevention. Pre-Exposure Prophlaxis (PrEP). https:\/\/www.cdc.gov\/hiv\/risk\/prep\/index.html. Accessed 18 March 2021."},{"key":"3592_CR5","volume-title":"Policy Brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Policy Brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). Geneva: World Health Organization; 2015."},{"key":"3592_CR6","unstructured":"PrEP Watch. The Global PrEP tracker. https:\/\/data.prepwatch.org\/. Accessed 18 March 2021."},{"issue":"12","key":"3592_CR7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/QAD.0000000000002598","volume":"34","author":"K Stankevitz","year":"2020","unstructured":"Stankevitz K, Grant H, Lloyd J, et al. Oral preexposure prophylaxis continuation, measurement and reporting. AIDS. 2020;34(12):1801\u201311.","journal-title":"AIDS"},{"key":"3592_CR8","doi-asserted-by":"crossref","unstructured":"de Dieu Tapsoba J, Zangeneh SZ, Appelmans E, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2020;1\u20139.","DOI":"10.1080\/09540121.2020.1822505"},{"issue":"9","key":"3592_CR9","doi-asserted-by":"publisher","first-page":"e1002885","DOI":"10.1371\/journal.pmed.1002885","volume":"16","author":"KK Mugwanya","year":"2019","unstructured":"Mugwanya KK, Pintye J, Kinuthia J, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16(9):e1002885.","journal-title":"PLoS Med"},{"key":"3592_CR10","unstructured":"Celum C, Bukusi E, Bekker LG, et al. PrEP initiation, persistence, and HIV seroconversion rates in African adolescent girls and young women (AGYW) from Kenya and South Africa: The POWER demonstration project. HIV Research for Prevention\u00a0conference (HIV R4P). Virtual, 2021 [Poster PE16.19]."},{"issue":"1","key":"3592_CR11","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3018(19)30335-2","volume":"7","author":"J Kinuthia","year":"2020","unstructured":"Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38\u201348.","journal-title":"Lancet HIV"},{"key":"3592_CR12","doi-asserted-by":"crossref","unstructured":"B\u00e4rnighausen K, Geldsetzer P, Matse S, et al. Qualitative accounts of PrEP discontinuation from the general population in Eswatini.\u00a0Cult Health Sex. 2020;1\u201317.","DOI":"10.1080\/13691058.2020.1770333"},{"issue":"10","key":"3592_CR13","doi-asserted-by":"publisher","first-page":"e0258542","DOI":"10.1371\/journal.pone.0258542","volume":"16","author":"E Rousseau","year":"2021","unstructured":"Rousseau E, Katz AWK, O\u2019Rourke S, et al. Adolescent girls and young women\u2019s PrEP-user journey during an implementation science study in South Africa and Kenya. PLoS ONE. 2021;16(10):e0258542.","journal-title":"PLoS ONE"},{"key":"3592_CR14","unstructured":"Joint United Nations Programme on HIV\/AIDS and the World Health Organization. Ethical considerations in\u00a0HIV prevention trials. 2021. Geneva: Licence: CC\u00a0BY-NC-SA\u00a03.0\u00a0IGO."},{"key":"3592_CR15","unstructured":"The South African Medical Research Council. Executive Summary of the Summit on the Standard of Care in Clinical Trials in Low-Middle Income Settings. 2017. https:\/\/www.samrc.ac.za\/sites\/default\/files\/publications\/2019-01-17\/ExecSumSummitStandardCare.pdf. Accessed 15 March 2021."},{"issue":"10195","key":"3592_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(19)31288-7","volume":"394","author":"Evidence for contraceptive options and HIV outcomes (ECHO) Trial Consortium","year":"2019","unstructured":"Evidence for contraceptive options and HIV outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303\u201313.","journal-title":"Lancet"},{"key":"3592_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s10461-020-03072-0","volume":"25","author":"I Beesham","year":"2021","unstructured":"Beesham I, Heffron R, Evans S, et al. Exploring the use of oral pre-exposure prophylaxis (PrEP) among women from Durban, South Africa as part of the HIV prevention package in a clinical trial. AIDS Behav. 2021;25:1112\u20139.","journal-title":"AIDS Behav"},{"issue":"5","key":"3592_CR18","doi-asserted-by":"publisher","first-page":"e25491","DOI":"10.1002\/jia2.25491","volume":"23","author":"I Beesham","year":"2020","unstructured":"Beesham I, Welch JD, Heffron R, et al. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. J Int AIDS Soc. 2020;23(5):e25491.","journal-title":"J Int AIDS Soc"},{"key":"3592_CR19","unstructured":"University of Witwatersrand. REDCap\u00ae.\u00a02020. https:\/\/redcap.core.wits.ac.za\/redcap\/. Accessed 30 March 2021."},{"key":"3592_CR20","unstructured":"StataCorp, College Station, Texas, USA. Copyright 1985\u20132015, StataCorp LP. http:\/\/www.stata.com. Accessed 30 June 2021."},{"key":"3592_CR21","doi-asserted-by":"publisher","unstructured":"Joseph Davey DL, Mvududu R, Mashele N, et al. Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: implications for maternal PrEP roll out in South Africa. Preprint. PmedRxiv\u00a02021.05.04.21256514;https:\/\/doi.org\/10.1101\/2021.05.04.21256514.","DOI":"10.1101\/2021.05.04.21256514"},{"issue":"6","key":"3592_CR22","doi-asserted-by":"publisher","first-page":"e1003670","DOI":"10.1371\/journal.pmed.1003670","volume":"18","author":"C Celum","year":"2021","unstructured":"Celum C, Hosek S, Tsholwana M, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670.","journal-title":"PLoS Med"},{"issue":"11","key":"3592_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","volume":"29","author":"JE Haberer","year":"2015","unstructured":"Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277\u201385.","journal-title":"AIDS"},{"issue":"1","key":"3592_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/COH.0000000000000220","volume":"11","author":"JE Haberer","year":"2016","unstructured":"Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11(1):10\u20137.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"3592_CR25","doi-asserted-by":"publisher","first-page":"e0248307","DOI":"10.1371\/journal.pone.0248307","volume":"16","author":"D Giovenco","year":"2021","unstructured":"Giovenco D, Gill K, Fynn L, et al. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence. PLoS ONE. 2021;16(3):e0248307.","journal-title":"PLoS ONE"},{"key":"3592_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-021-03374-x","author":"A Moran","year":"2021","unstructured":"Moran A, Mashele N, Mvududu R, et al. Maternal PrEP use in HIV-uninfected pregnant women in South Africa: role of stigma in PrEP initiation, retention and adherence. AIDS Behav. 2021. https:\/\/doi.org\/10.1007\/s10461-021-03374-x.","journal-title":"AIDS Behav"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-022-03592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-022-03592-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-022-03592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T11:22:42Z","timestamp":1656933762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-022-03592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3592"],"URL":"https:\/\/doi.org\/10.1007\/s10461-022-03592-x","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"15 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ECHO trial was approved by University of Witwatersrand Human Research Ethics Committee (Wits HREC) and the FHI360 ethics review board. This ancillary study was approved by Wits HREC (Reference 141112).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from women to participate in the ECHO trial, and additional informed consent was obtained to participate in this ancillary study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}